Over the past few years, long-term inhaled glucocorticoid therapy for asthma has been accepted by more and more patients, and at the same time, as the treatment experience continues to be enriched, new problems and new understanding, also continue to emerge, and the 2014 Global Guidelines for the Prevention and Treatment of Asthma (GINA) further pointed out that asthma is a heterogeneous disease, and the principle of individualization should be emphasized in the treatment. For example, many foreign articles have proposed the use of intermittent nebulized inhaled high-dose hormone regimens for certain patients, which are considered to be no less effective than long-term continuous inhaled hormones, and have the advantages of less total drug use and easier acceptance by patients. In recent years, this therapy has been used for diseases similar to or related to asthma, such as wheezing after recurrent viral infections, post-infectious cough, and mycoplasma pneumonia. Asthma is indeed a heterogeneous disease, and not all problems can be solved by one solution. It is very important to further communicate between doctors and patients in order to further improve the treatment of these diseases.